RetinAI and Novartis ink multi-year software license agreement

RetinAI’s Discovery UNITY platform leverages clinical and evidence from the real world to improve understanding of treatment outcomes. The AI capabilities integrated with the platform speed up data processing with expert-level analysis and insights extraction. Customers can thus apply RetinAI’s most advanced tools to support their research and clinical development pipeline in Ophthalmology, accelerating data analytics and research workflows. These tools can enhance understanding of eye diseases and help better define patient populations around the globe.

Companies like Novartis can use the platform to characterise diseases and patient outcomes based on at-scale data organisation, data aggregation and applied AI from regulatory-approved and AI research models for diseases in Ophthalmology. RetinAI’s AI models include applications in Age-related Macular Degeneration (including Geographic Atrophy), Diabetic Retinopathy, Diabetic Macular Edema, Retinal Vein Occlusion and Glaucoma.

Building on their existing relationship, RetinAI and Novartis are entering a long-term collaboration with a multi-year software license Agreement for Discovery UNITY. “We are very excited to expand our existing relationship with Novartis and see them as an important partner in implementing the future of digital precision medicine. We believe RetinAI’s UNITY platform will redefine how data analysis is performed in drug development, creating opportunities for more cost-effective, target-based research in discovery and clinical trial design,” commented Carlos Ciller, CEO of RetinAI on the achievement. The platform is CE-marked and has received clearance from the U.S. Food and Drugs Administration.

(Press release/RAN)
Photo: RetinAI team at the ARVO2022 Annual Meeting in Colorado Convention Center.